Therapy escalation following an elevated HbA1c in adults aged 45 years and older living with diabetes in Australia: a real-world observational analysis
figureposted on 2020-09-14, 18:31 authored by Ying Xie, Jannah Baker, Tamara Young, Min Jun, Louisa Sukkar, Anna Campain, Amy Kang, Alan Cass, Ji Hu, David Peiris, Carol Pollock, Germaine Wong, Sophia Zoungas, Kris Rogers, Meg Jardine, Carinna Hockham, the EXTEND45 Steering Committee
Stepwise escalation of glucose-lowering therapy to more intensive regimens is an integral component of type 2 diabetes management (1). Early blood glucose control is associated with beneficial effects on long-term micro- and macrovascular outcomes (2). Understanding factors associated with time to therapy escalation following an elevated glycated hemoglobin (HbA1c) may inform interventions to facilitate timely control. We used linked real-world data to examine time to therapy escalation following a recorded HbA1c ≥8.0% (64 mmol/mol) and associated factors.